Search Result

Results for "

FKBPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FKBP (49) Antibiotic (7) Apoptosis (6) AUTACs (2) Autophagy (16) Bacterial (9) Biochemical Assay Reagents (1) Calcium Channel (1) Drug Intermediate (1) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (5) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (3) Fungal (2) HSP (2) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (6) mTOR (8) Parasite (1) Phosphatase (5) Progesterone Receptor (3) PROTACs (15) Small Interfering RNA (siRNA) (14)
By Research Areas:	Cancer (46) Endocrinology (3) Infection (6) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (5)
Oligonucleotides:	Pre-designed siRNA Sets (14) siRNAs (14)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: FKBP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114872

SLF	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF can be used in the synthesis of PROTAC .

HY-114872A

SLF TFA	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF TFA can be used in the synthesis of PROTAC .

HY-135345

*PROTAC FKBP* Degrader-3** 1 Publications Verification	PROTACs FKBP	Cancer
PROTAC FKBP Degrader-3 is a PROTAC that comprises a *FKBP* ligand binding group, a linker and an von Hippel-Lindau binding group. PROTAC FKBP Degrader-3 is a potent *FKBP* degrader .

HY-107452

SLF-amido-C2-COOH PROTAC FKBP12-binding moiety 1	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for *FKBP* (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs .

HY-134184

AUTAC2	AUTACs Autophagy	Inflammation/Immunology Cancer
AUTAC2 is a *FKBP12*-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .

HY-113646

Shield-2	FKBP	Others
Shield-2 is an efficient stabilizing ligand binding to the FKBP (F36V) protein with a dissociation constant of 29 nM. Shield-2 binds tightly to the *FKBP* mutants destabilizing domains and prevents degradation, thus providing small molecule regulation over intracellular protein levels .

HY-W017542

L-Pyrohomoglutamic acid	Drug Intermediate Biochemical Assay Reagents	Others
L-Pyrohomoglutamic acid is an amino acid building block. L-Pyrohomoglutamic acid can be used to synthesize ligands for FK506-binding proteins (FKBPs) and histone deacetylase (HDAC) inhibitors .

HY-153990

FKBP51F67V-selective antagonist Ligand2	FKBP	Neurological Disease
FKBP51F67V-selective antagonist Ligand2 (example 3-3) is a potent FKBP51 F67V-selective antagonist ligand. FKBP51F67V-selective antagonist Ligand2 reverses the anxiogenic phenotype induced by overexpression of FKBP51 F67V in the amygdala. FKBP51F67V-selective antagonist Ligand2 binds to FKBP51 F67V, but not to wild-type FKBP51 or FKBP52 .

HY-158131

FKBP51-Hsp90-IN-2	FKBP HSP	Neurological Disease Cancer
FKBP51-Hsp90-IN-2 (Compound E08) is a selective *FKBP51-Hsp90* protein-protein interaction inhibitor with IC₅₀ values of 0.4 µM and 5 µM for *FKBP51* and *FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP*51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .

HY-158130

FKBP51-Hsp90-IN-1	FKBP HSP	Neurological Disease Metabolic Disease Cancer
FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the *FKBP51-Hsp90* protein-protein interaction, with an IC₅₀ value of 0.1 μM against *FKBP51. FKBP*51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .

HY-114421

FKBP12 PROTAC dTAG-13 2 Publications Verification dTAG-13	PROTACs FKBP	Cancer
FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 ^F36V and CRBN, thereby selectively degrading FKBP12 ^F36V .

HY-123941

FKBP12 PROTAC dTAG-7 1 Publications Verification dTAG-7	PROTACs FKBP Epigenetic Reader Domain	Cancer
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12 ^F36V with expression of FKBP12 ^F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN .

HY-102079

SAFit1	FKBP	Neurological Disease Metabolic Disease
SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a K_i of 4±0.3 nM .

HY-112210

Shield-1 4 Publications Verification Shld1	FKBP	Others
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to *mutated FKBP* (mtFKBP)*, allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP*12-derived destabilization domain (DD) .

HY-130835

FKBP12 PROTAC RC32 RC32	PROTACs FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent *FKBP12* degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .

HY-147098

dTAG-47	PROTACs FKBP	Cancer
dTAG-47, heterobifunctional dTAG molecule, targets mutant FKBP12 (FKBP12 ^F36V). FKBP12 ^F36V serves as a degradation tag (dTAG) and is fused to a protein of interest. dTAG-47 can be used for the research of basal-like breast cancers (BBC) .

HY-RS04956

FKBP10 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP10 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP10 Human Pre-designed siRNA Set A FKBP10 Human Pre-designed siRNA Set A

HY-RS04957

FKBP11 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP11 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP11 Human Pre-designed siRNA Set A FKBP11 Human Pre-designed siRNA Set A

HY-RS04958

FKBP14 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP14 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP14 Human Pre-designed siRNA Set A FKBP14 Human Pre-designed siRNA Set A

HY-RS04959

FKBP15 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP15 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP15 Human Pre-designed siRNA Set A FKBP15 Human Pre-designed siRNA Set A

HY-RS04960

FKBP1A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP1A Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP1A Human Pre-designed siRNA Set A FKBP1A Human Pre-designed siRNA Set A

HY-RS04962

FKBP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP2 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP2 Human Pre-designed siRNA Set A FKBP2 Human Pre-designed siRNA Set A

HY-RS04963

FKBP3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP3 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP3 Human Pre-designed siRNA Set A FKBP3 Human Pre-designed siRNA Set A

HY-RS04964

FKBP4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP4 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP4 Human Pre-designed siRNA Set A FKBP4 Human Pre-designed siRNA Set A

HY-RS04965

FKBP5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP5 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP5 Human Pre-designed siRNA Set A FKBP5 Human Pre-designed siRNA Set A

HY-RS04966

FKBP6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP6 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP6 Human Pre-designed siRNA Set A FKBP6 Human Pre-designed siRNA Set A

HY-RS04967

FKBP7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP7 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP7 Human Pre-designed siRNA Set A FKBP7 Human Pre-designed siRNA Set A

HY-RS04968

FKBP8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP8 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP8 Human Pre-designed siRNA Set A FKBP8 Human Pre-designed siRNA Set A

HY-RS04969

FKBP9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP9 Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP9 Human Pre-designed siRNA Set A FKBP9 Human Pre-designed siRNA Set A

HY-103634

dFKBP-1 1 Publications Verification	PROTACs FKBP	Cancer
dFKBP-1 is a potent and PROTAC-based *FKBP12* degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of *FKBP12, the Thalidomide based Cereblon* ligand and a linker .

HY-RS04961

FKBP1B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FKBP1B Human Pre-designed siRNA Set A contains three designed siRNAs for FKBP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FKBP1B Human Pre-designed siRNA Set A FKBP1B Human Pre-designed siRNA Set A

HY-106345

ILS-920	FKBP Calcium Channel	Neurological Disease Inflammation/Immunology
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin *FKBP52* and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for *FKBP52* versus FKBP12 .

HY-150410

TSPO ligand-3	AUTACs	Cancer
TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells .

HY-129363

AP1867-3-(aminoethoxy)	Ligands for Target Protein for PROTAC FKBP	Cancer
AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for *FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP*12 F36V degrader .

HY-145514

dTAGV-1 TFA	PROTACs	Cancer
dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12 ^F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12 ^F36V-Nluc in vivo .

HY-153806

RapaBlock ZZY05-092	FKBP	Cancer
RapaBlock is a potent, non-immunosuppressive and brain-impermeable *FKBP12* ligand .

HY-161794

SP3N	FKBP Ligands for Target Protein for PROTAC	Cancer
SP3N is a specific degrader of the prolyl isomerase *FKBP12. The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCFFBXO22 ligase for FKBP12* degradation. SP3N may be used in research for cancer .

HY-161157

dTAG-13-NEG	PROTACs	Cancer
dTAG-13-NEG is a negative control of dTAG-13. dTAG-13 (HY-114421), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest .

HY-114434

AP1867 3 Publications Verification	FKBP	Cancer
AP1867 is a synthetic FKBP12 ^F36V-directed ligand .

HY-145514C

dTAGV-1 hydrochloride	FKBP PROTACs	Cancer
dTAGV-1 hydrochloride is the hydrochloride form of dTAGV-1 that is a small molecule degrader of *FKBP12* .

HY-10218

Everolimus 80+ Cited Publications RAD001; SDZ-RAD	mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-10218S

Everolimus-d4 RAD001-d₄; SDZ-RAD-d₄	mTOR FKBP Autophagy Apoptosis	Cancer
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-P4581

Suc-Ala-Leu-Pro-Phe-pNA Suc-ALPF-pNA	FKBP	Others
Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a substrate of FK-506 binding protein (FKBP) .

HY-10218R

Everolimus (Standard) RAD001 (Standard); SDZ-RAD (Standard)	mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-16046

Rimiducid 30+ Cited Publications AP1903	FKBP Apoptosis	Cancer
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the *FKBP* domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

HY-145712

ElteN378	FKBP	Cancer
ElteN378 is an inhibitors of *FKBP12e*. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .

HY-129610

KB02-SLF	PROTACs FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear *FKBP12* degrader (molecular glue). KB02-SLF promotes nuclear *FKBP12* degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .

HY-145514A

dTAGV-1-NEG	PROTACs FKBP	Cancer
dTAGV-1-NEG is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1 is an FKBP12 ^F36V-selective degrader .

HY-102080

SAFit2 4 Publications Verification	FKBP	Cancer
SAFit2 is a highly potent, highly selective FK506-binding protein 51 (FKBP51) inhibitor with a K_i of 6 nM and also enhances AKT2-AS160 binding .

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

Cat. No.	Product Name	Target	Research Area

HY-P4581

Suc-Ala-Leu-Pro-Phe-pNA Suc-ALPF-pNA	FKBP	Others
Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a substrate of FK-506 binding protein (FKBP) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13756A

Tacrolimus monohydrate 75+ Cited Publications FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate	Infection Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Disease Research Inflammation/Immunology Disease Research Fields	Phosphatase FKBP Autophagy Bacterial Antibiotic
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-10219

Rapamycin Maximum Cited Publications 888 Publications Verification Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-13756

Tacrolimus 75+ Cited Publications FK506; Fujimycin; FR900506	Infection Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Animals Classification of Application Fields Antibiotics Source classification Disease Research Inflammation/Immunology Disease Research Fields	Phosphatase FKBP Bacterial Autophagy Antibiotic
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-B0652

Etonogestrel 3-Oxodesogestrel; 3-keto-Desogestrel	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce *FKBP51* mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-10219R

Rapamycin (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Source classification Disease Research Endogenous metabolite	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-13756AR

Tacrolimus (monohydrate) (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Source classification Disease Research	Phosphatase FKBP Autophagy Bacterial Antibiotic
Tacrolimus (monohydrate) (Standard) is the analytical standard of Tacrolimus (monohydrate). This product is intended for research and analytical applications. Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-13756R

Tacrolimus (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Animals Antibiotics Source classification Disease Research	Phosphatase FKBP Bacterial Autophagy Antibiotic
Tacrolimus (Standard) is the analytical standard of Tacrolimus. This product is intended for research and analytical applications. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-B0652R

Etonogestrel (Standard)	Structural Classification Source classification Endogenous metabolite Steroids	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (Standard) is the analytical standard of Etonogestrel. This product is intended for research and analytical applications. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

Cat. No.	Product Name	Chemical Structure

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-13756S

Tacrolimus-13C,d2
Tacrolimus- ¹³C,d₂ is a ¹³C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-B0652S1

Etonogestrel-d6
Etonogestrel-d₆ is deuterium labeled Etonogestrel. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs[1]. Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs)[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks